| Literature DB >> 32943003 |
Hetao Huang1, Jianke Pan2, Weiyi Yang2, Jiongtong Lin1, Yanhong Han1, Kai Lan3, Lingfeng Zeng2,4, Guihong Liang2,4, Jun Liu5,6.
Abstract
BACKGROUND: The purpose of this case report was to report a case of Cryptococcus laurentii infection in the left knee of a previously healthy 29 year old male patient. CASEEntities:
Keywords: Case report; Cryptococcus laurentii; Fungal infection
Mesh:
Substances:
Year: 2020 PMID: 32943003 PMCID: PMC7500548 DOI: 10.1186/s12879-020-05401-z
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1a. MR imaging indicated bone marrow edema of the proximal tibia, distal femur and patella, posterior horn tears of the medial and lateral meniscus (III°), and joint effusion, all of which confirmed the clinical diagnosis of purulent arthritis. b(i,ii). MR imaging after knee arthroscopic surgery revealed that the joint swelling was reduced, the proximal tibia edema was improved, and the left lateral meniscus was repaired, while the other conditions were similar to those observed in the first MR images. b(iii). Left knee DR revealed swelling of the soft tissue of the left knee joint, and the bone was loose, indicative of osteoporosis. c. The left knee was swollen; the longitudinal range of swelling was 29 cm, and the knee circumference at the most swollen part was 47.4 cm. Purulent fluid was withdrawn from the left knee
Fig. 2a. Intraoperative manifestations of knee joint. b. Yellow, purulent liquid was drained from the medial drainage tube, and it became obstructed. c. After more than three weeks of antibiotic treatment, the wound of the lateral drainage tube healed without effusion
Fig. 3a.Two months later, a physical examination showed no swelling, pain or warmth of the left knee; the medial, middle and lateral operative wounds were healed well; and the infection did not recur. b.Three months later, the left knee was painless, and the range of motion of the left knee was 0–120°
Timeline
| Timeline | Clinical manifestations / Examination results | Treatment |
|---|---|---|
| March 2016 | Stabbed by plants on the posterolateral side of his left knee.Pain, warmth and swelling in the left knee joint. | Antibiotics, intra-articular puncture with knee fluid aspiration and steroidal injection. |
| November 4th, 2016 | Admission of patient. The left knee was moderately swollen without effusion and the local skin temperature was slightly increase. | |
| November 7th, 2016 | Surgical of the left knee with a synovectomy and meniscus repair under arthroscopy. Postoperatively, the left knee was irrigated with Gentamicin sulfate and other routine treatments were carried out for 5 days. | |
| November 15th, 2016 | The patient’s symptoms were relieved and discharged. | |
| November 23th, 2016 | Culture result of the patient’s operative sample revealed a | Inform the patient to return to the hospital for treatment. |
| December 12th, 2016 | Admission of patient.Left knee was moderately swollen and warm, and more than 5 ml of yellow purulent fluid was withdrawn | 200 mg of intravenous (IV) voriconazole every 12 h (q12 h; 400 mg q12 h on the first day), debridement and irrigation of the left knee with amphotericin B until the infection was controlled and 400 mg of fluconazole per os (PO) q24 h maintained for 6 months. |
| December 15th, 2016 | Incision, debridement and irrigation of the left knee. Suction, resection and repeated irrigation with iodophors, hydrogen peroxide and normal saline in the knee joint were performed thoroughly, and 2 flushing tubes and 2 suction drainage tubes were placed in the knee joint. Postoperatively, an antifungal regimen was carried out. | |
| December 27th, 2016 | The tube became obstructed. | Secondary incision, debridement and irrigation of the left knee was performed.The antifungal regimen and knee joint irrigation with amphotericin B were continued. |
| January 6th, 2017, | The skin around the drainage tube on the medial side of the left knee was a mild red color and swollen. ESR:44 mm/h, hsCRP:150.9 mg/dL. | IV clindamycin hydrochloride (0.45 g, q8 h) was administered for a week, and then IV clindamycin hydrochloride was discontinued and replaced with clindamycin palmitate hydrochloride dispersible tablets (150 mg PO qid). |
| January 11th, 2017, | ESR:29 mm/h, hsCRP:19.5 mg/dL. | The left knee joint irrigation was discontinued, intravenous voriconazole was also discontinued, fluconazole 400 mg IV q24 h was initiated, and the lateral flushing tube and drainage tube were maintained to continue draining the joint liquid. |
| January 25th, 2017, | The operative wound of the lateral drainage tube slightly effused a light-yellow liquid, so the liquid sample was sent for culture, and the result revealed | Clindamycin palmitate hydrochloride dispersible tablets were discontinued and replaced with ciprofloxacin lactate (0.2 g IV q12 h). |
| January 30th, 2017 | No swelling, and the operative wounds were healing without effusion, and the joint was able to be moved well. | Discharged from hospital.Antifungal and antibacterial therapy of fluconazole (400 mg PO qd) and ciprofloxacin lactate were continued for 6 months and 3 weeks. |
| April, 2017 | Outpatient follow-up.There was no swelling, pain or warmth of the left knee; the medial, middle and lateral operative wounds were healed well with no infection recurrence; and the range of motion of the left knee was 0–120° | |
Summary of Infectious Diseases Society of America guidelines for the treatment of fungal osteoarticular infections
| Category | Treatment | Comments |
|---|---|---|
| Osteoarticular infections are not specifically addressed in current IDSA guidelinesRecommendations for extrapulmonary non-CNS cryptococcosis in immunocompetent patients: follow treatment protocol for CNS disease (see guidelines for separate recommendations for HIV-positive patients and for transplant recipients)Induction therapy:1. AmB plus flucytosine for 4 wk.2. AmB for 6 wk.3. Liposomal AmB or ABLC combined with flucytosine, if possible, for 4 wk.; or4. AmB plus flucytosine for 2 wk. (for patients at low risk for therapeutic failure; see guidelines)Consolidation therapy: fluconazole (400–800 mg/d) for 8 wk.Maintenance therapy: fluconazole (200 mg/d) for 6–12 moPatients without cryptococcemia and with a single site of infection and no immunosuppressive risk factors:Fluconazole for 6–12 moDepending on immune status, patients may require long-term secondary prophylaxis with fluconazole | ||
| Fluconazole, or Echinocandin (caspofungin, micafungin, or anidulafungin) for at least 2 wk. followed by fluconazole, or Liposomal AmB for at least 2 wk. followed by fluconazole | Choice of antifungal agent should be guided by susceptibility testingDuration of treatment:Septic arthritis: 6 wk.Osteomyelitis: 6–12 mo for osteomyelitis | |
| Primary: voriconazoleAlternative: liposomal AmBSalvage:ABLCCaspofunginMicafunginPosaconazoleItraconazole | Duration: minimum of 8 wk., to > 6 mo Guidelines recommend following same treatment protocols described for invasive pulmonary aspergillosis, but note that there is little experience with echinocandins in the treatment of aspergillus OAI | |
| Mild-moderate disease: fluconazole or itraconazole Severe disease: liposomal AmB for 3 mo followed by fluconazole or itraconazole | Duration of therapy: 3 y to lifelong | |
| Mild-moderate disease: itraconazole Severe disease: liposomal AmB for 2–6 wk., followed by itraconazole | Histoplasma osteoarticular infections usually occur in the setting of disseminated disease. Duration of therapy for disseminated disease: at least 12 mo | |
| Mild-moderate disease: itraconazole Severe disease: liposomal AmB for 2 wk. followed by itraconazole | Recommended duration of therapy for osteoarticular disease: at least 12 mo | |
| Preferred: itraconazole Alternative: liposomal AmB with change to itraconazole after a favorable response is achieved | Recommended duration of therapy for osteoarticular disease: at least 12 mo | |